Krystal Biotech Inc (KRYS) Receives $35.88 Average Target Price from Analysts

Krystal Biotech Inc (NASDAQ:KRYS) has received an average recommendation of “Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $35.88.

A number of equities research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Krystal Biotech in a research note on Monday, August 6th. Cantor Fitzgerald assumed coverage on Krystal Biotech in a research note on Monday, September 10th. They issued an “overweight” rating and a $28.00 price objective for the company. William Blair assumed coverage on Krystal Biotech in a research note on Tuesday, July 10th. They issued an “outperform” rating for the company. Zacks Investment Research raised Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Saturday, August 11th. Finally, HC Wainwright assumed coverage on Krystal Biotech in a research note on Monday, September 24th. They issued a “buy” rating and a $32.00 price objective for the company.

In related news, insider Krish S. Krishnan bought 25,000 shares of the stock in a transaction that occurred on Thursday, October 18th. The stock was purchased at an average cost of $20.00 per share, with a total value of $500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 45.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. P.A.W. Capital Corp acquired a new position in Krystal Biotech during the 3rd quarter worth $527,000. Acadian Asset Management LLC grew its stake in Krystal Biotech by 68.5% during the 3rd quarter. Acadian Asset Management LLC now owns 20,558 shares of the company’s stock worth $361,000 after purchasing an additional 8,356 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Krystal Biotech by 75.4% during the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares in the last quarter. 21.77% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ KRYS traded down $0.83 during trading on Tuesday, reaching $22.67. The stock had a trading volume of 138,337 shares, compared to its average volume of 160,072. Krystal Biotech has a fifty-two week low of $8.03 and a fifty-two week high of $24.89.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.12. As a group, research analysts anticipate that Krystal Biotech will post -1.01 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

See Also: How Do Tariffs Affect Trade Balances?

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply